Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs KB Financial Group, Inc. (KB) Price & Performance

Boston Scientific CorporationTrade
KB Financial Group, Inc.Trade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs KB Financial Group, Inc. — how do they compare? Boston Scientific Corporation trades at $51.16 (market cap $71.46B), while KB Financial Group, Inc. trades at $117.53 (market cap $42.79B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXKB
Market Cap
$71.46B$42.79B
Sector
HealthFinancials
52-Week High
$108.14$124.01
52-Week Low
$42.63$77.50
Enterprise Value
$83.55B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

KB Financial Group, Inc.

KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.

The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About KB Financial Group, Inc.

KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.

Read more on KB